FI104255B1 - Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi - Google Patents

Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi

Info

Publication number
FI104255B1
FI104255B1 FI915073A FI915073A FI104255B1 FI 104255 B1 FI104255 B1 FI 104255B1 FI 915073 A FI915073 A FI 915073A FI 915073 A FI915073 A FI 915073A FI 104255 B1 FI104255 B1 FI 104255B1
Authority
FI
Finland
Prior art keywords
preparation
fusion proteins
serum albumin
human serum
proteins containing
Prior art date
Application number
FI915073A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI104255B (fi
FI915073A0 (fi
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Publication of FI915073A0 publication Critical patent/FI915073A0/fi
Application granted granted Critical
Publication of FI104255B publication Critical patent/FI104255B/fi
Publication of FI104255B1 publication Critical patent/FI104255B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI915073A 1989-04-29 1991-10-28 Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi FI104255B1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8909916 1989-04-29
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides
PCT/GB1990/000650 WO1990013653A1 (en) 1989-04-29 1990-04-26 Fusion proteins containing n-terminal fragments of human serum albumin
GB9000650 1990-04-26

Publications (3)

Publication Number Publication Date
FI915073A0 FI915073A0 (fi) 1991-10-28
FI104255B FI104255B (fi) 1999-12-15
FI104255B1 true FI104255B1 (fi) 1999-12-15

Family

ID=10656000

Family Applications (1)

Application Number Title Priority Date Filing Date
FI915073A FI104255B1 (fi) 1989-04-29 1991-10-28 Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi

Country Status (12)

Country Link
EP (1) EP0470165A1 (de)
JP (1) JP2781459B2 (de)
KR (1) KR100227167B1 (de)
AU (1) AU630450B2 (de)
CA (1) CA2015687C (de)
FI (1) FI104255B1 (de)
GB (2) GB8909916D0 (de)
HU (1) HUT61049A (de)
IE (1) IE67651B1 (de)
IL (1) IL94243A (de)
WO (1) WO1990013653A1 (de)
ZA (1) ZA903237B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
GB9408466D0 (en) * 1994-04-27 1994-06-22 Univ Nottingham Cloning and functional expression of neurotoxins
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
PE99498A1 (es) * 1996-07-26 1999-01-21 Novartis Ag Polipeptidos de fusion
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
WO1999037793A1 (en) 1998-01-23 1999-07-29 Novo Nordisk A/S Process for making desired polypeptides in yeast
DE69933216T2 (de) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ATE429486T1 (de) 2001-08-15 2009-05-15 Takara Bio Inc Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
TW201043699A (en) 2002-03-25 2010-12-16 Takara Bio Inc Process for producing cytotoxic lymphocyte
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US8927273B2 (en) 2003-08-22 2015-01-06 Takara Bio Inc. Process for producing cytotoxic lymphocytes
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
WO2006067511A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2049560B1 (de) 2006-07-13 2013-05-15 Novozymes Biopharma DK A/S Verfahren zur herstellung von partikeln aus proteinhaltigem material
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
KR20200044138A (ko) * 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
EP2968587A2 (de) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Serumalbumingebundene fibronectin-gerüstdomänen oder daran bindendes element
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
EP3711772A1 (de) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Rekombinante proteine und fusionsproteine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides

Also Published As

Publication number Publication date
AU5564690A (en) 1990-11-29
FI104255B (fi) 1999-12-15
KR100227167B1 (ko) 1999-10-15
IE67651B1 (en) 1996-04-17
AU630450B2 (en) 1992-10-29
JPH04506598A (ja) 1992-11-19
IL94243A0 (en) 1991-01-31
FI915073A0 (fi) 1991-10-28
GB2246783A (en) 1992-02-12
HUT61049A (en) 1992-11-30
JP2781459B2 (ja) 1998-07-30
IL94243A (en) 1995-10-31
GB2246783B (en) 1992-10-14
KR920701451A (ko) 1992-08-11
CA2015687C (en) 2000-08-29
ZA903237B (en) 1991-03-27
CA2015687A1 (en) 1990-10-29
HU904413D0 (en) 1992-01-28
GB8909916D0 (en) 1989-06-14
GB9119043D0 (en) 1991-12-04
EP0470165A1 (de) 1992-02-12
IE901554L (en) 1990-10-29
WO1990013653A1 (en) 1990-11-15

Similar Documents

Publication Publication Date Title
GB2246783B (en) Fusion proteins containing n-terminal fragments of human serum albumin
FI893702A7 (fi) Menetelmä ihmisen seerumialbumiinin ja muiden heterologisten proteiinien mikrobiologiseksi valmistamiseksi hiivasta
FI884051L (fi) Menetelmä stabiloitujen humaaniproteiinivalmisteiden valmistamiseksi
KR100386762B1 (ko) 재조합사람혈청알부민의제조방법
FI892208A7 (fi) Menetelmä ja välituote aggregoitumista ehkäisevien peptidien valmistamiseksi
EP0324647A3 (en) Vector for the expression of fusion proteins and protein immunogens
AU626183B2 (en) Chimaeric hepadnavirus core antigen proteins
EP0243929A3 (en) Polypeptide and protein derivatives and process for their preparation
FI20002013L (fi) HCV-fuusioproteiini
PT86600A (pt) Process for the preparation of anticoagulant peptides
FI864654L (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
FI903917A7 (fi) Menetelmä metalli-radionuklideilla leimattujen proteiinien valmistamis eksi
PT87688A (pt) Hybrid protein c and method for its preparation
FI881743L (fi) Menetelmä bifunktionaalisten proteiinien valmistamiseksi
EP0209543A4 (de) Peptidfragmente menschlicher apolipoproteine, typspezifische antikörper und verwendungsverfahren.
ZA895821B (en) Method for the microbiological preparation of human serum albumin and other heterologous proteins from a yeast
FI904357A7 (fi) Menetelmä proteiinin C aktivoimiseksi
PT87207A (pt) Process for preparing recombinant htlv-iii proteins and uses thereof
IL94526A0 (en) Method for c-terminal modification of proteins
AU1216988A (en) Immunogenic fusion proteins which contain Epstein-Barr virus protein
DK284489D0 (da) Fusionsproteiner
DK241688A (da) Fremgangsmaade til fremstilling af fusionsproteiner
NO891926L (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
FI893168A7 (fi) Menetelmä proteiinien valmistamiseksi
HU895916D0 (en) Process for the preparation of monoclonal antibody recognaizing reg protein

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: NOVOZYMES DELTA LIMITED

Free format text: NOVOZYMES DELTA LIMITED

PC Transfer of assignment of patent

Owner name: NOVOZYMES BIOPHARMA UK LIMITED

Free format text: NOVOZYMES BIOPHARMA UK LIMITED